Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | C1R | P00736 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | F2R | P25116 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | IDH2 | P48735 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6230288 | 0.86 | GAA (0.43) | GAAEPHX2DDB1CRBNC1R | |
| SCHEMBL2089818 | 0.86 | ALDH1A1 (0.38) | GAAEPHX2IDO1CHRM2ALDH1A1 | |
| SCHEMBL2093975 | 0.82 | CHRM2 (0.49) | GAAEPHX2DDB1CRBNC1R | |
| SCHEMBL7736582 | 0.79 | GAA (0.43) | GAAEPHX2DDB1CRBNC1R | |
| SCHEMBL18622663 | 0.79 | CA12 (0.46) | GAAEPHX2DDB1CRBNC1R | |
| SCHEMBL7733811 | 0.79 | GBA1 (0.54) | GAAEPHX2DDB1CRBNC1R | |
| SCHEMBL5645988 | 0.79 | GAA (0.49) | GAAEPHX2DDB1CRBNC1R | |
| SCHEMBL3192934 | 0.78 | EPHX2 (0.57) | GAAEPHX2DDB1CRBNC1R | |
| SCHEMBL23502593 | 0.77 | GAA (0.42) | GAAEPHX2DDB1CRBNC1R | |
| SCHEMBL1022424 | 0.76 | CHRM2 (0.58) | GAACHRM2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11289238-B2 | Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210174983-A1 | COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC | 2021-06-10 | — | — | US | disclosed |
| US-9844516-B2 | Sigma ligands for use in the prevention and/or treatment of post-operative pain | Laboratorios De Dr. Esteve (ES) | 2017-12-19 | — | — | US | disclosed |
| US-9789115-B2 | Use of sigma ligands in opioid-induced hyperalgesia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-10-17 | — | — | US | disclosed |
| US-9782483-B2 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2017-10-10 | — | — | US | disclosed |
| US-20130324535-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-12-05 | — | — | US | disclosed |
| US-20130158033-A1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-20 | — | — | US | disclosed |
| US-20130109692-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-05-02 | — | — | US | disclosed |
| US-20120302568-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-11-29 | — | — | US | disclosed |
| EP-1530562-A1 | OPTICALLY ACTIVE 1-(FLUORO-,TRIFLUOROMETHYL-OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVES AND PROCESS FOR PRODUCING SAME | Central Glass Company, Limited (JP) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004022521-A1 | OPTICALLY ACTIVE 1-(FLUORO-,TRIFLUOROMETHYL-OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVES AND PROCESS FOR PRODUCING SAME | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302568-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN | OPRL1, OPRK1, SIGMAR1 | GAA 4365/4885EPHX2 1586/4885PGK1 3086/4885 |
| US-20130158033-A1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | OPRL1, OPRK1, OPRM1 | GAA 3260/4885EPHX2 1002/4885PGK1 3626/4885 |
| US-20130109692-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | SIGMAR1, SFN, TMEM97 | GAA 1690/4885EPHX2 4177/4885PGK1 4266/4885 |
| US-20130324535-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | SIGMAR1, OPRL1, OPRK1 | GAA 4190/4885EPHX2 3611/4885PGK1 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.